Targeted Therapy Making Progress with Pleural Mesothelioma
Future treatment of pleural mesothelioma cancer continued its move toward a more personalized, targeted approach with the latest results from a multi-center clinical trial involving tazemetostat, a novel protein inhibitor.
Tazemetostat, also known as the brand name Tazverik, showed impressive effectiveness in a second line setting for patients with the BAP1 genetic mutation.
The disease control rate for patients was 54.1% at 12 weeks and 32.8% at 24 weeks, numbers that exceeded expectations. There currently is no FDA-approved second-line treatment for pleural mesothelioma, an aggressive cancer with no cure caused pri...
Source: Asbestos and Mesothelioma News - May 24, 2022 Category: Environmental Health Authors: Sophia Clifton Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
How Fast Does Synovial Sarcoma Grow?
Title: How Fast Does Synovial Sarcoma Grow?Category: Diseases and ConditionsCreated: 2/3/2022 12:00:00 AMLast Editorial Review: 2/3/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 3, 2022 Category: Cancer & Oncology Source Type: news
What Does a Synovial Sarcoma Feels Like?
Title: What Does a Synovial Sarcoma Feels Like?Category: Diseases and ConditionsCreated: 2/1/2022 12:00:00 AMLast Editorial Review: 2/1/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - February 1, 2022 Category: Cancer & Oncology Source Type: news
How Bad Is Synovial Sarcoma?
Title: How Bad Is Synovial Sarcoma?Category: Diseases and ConditionsCreated: 1/14/2022 12:00:00 AMLast Editorial Review: 1/14/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - January 14, 2022 Category: Cancer & Oncology Source Type: news
Can Synovial Sarcoma Be Cured?
Title: Can Synovial Sarcoma Be Cured?Category: Diseases and ConditionsCreated: 8/27/2021 12:00:00 AMLast Editorial Review: 8/27/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 27, 2021 Category: Cancer & Oncology Source Type: news
Huntsman Cancer Institute researchers yield new insights into origins of synovial sarcoma
(Huntsman Cancer Institute) A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and spreads. The study was led by Kevin B. Jones, MD and Bradley R. Cairns, PhD from Huntsman Cancer Institute. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 2, 2021 Category: Cancer & Oncology Source Type: news
Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune's phase 2 SPEARHEAD-1 trial
(Evoke KYNE) Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 20, 2021 Category: Cancer & Oncology Source Type: news
Dana-Farber study advances understanding of rare sarcoma
In this study, scientists discover how abnormal protein disrupts gene expression in synovial sarcoma. For the first time, scientists discover the molecular basis for the cancer-specific targeting properties of the culprit fusion protein found in synovial sarcoma (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 3, 2020 Category: Cancer & Oncology Source Type: news
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors
(University of Texas M. D. Anderson Cancer Center) The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 29, 2020 Category: International Medicine & Public Health Source Type: news
Teenager with incurable cancer refuses to stop smiling despite spending Christmas in hospital
Joseph Lunn, from Mitcham, south London, was diagnosed with synovial sarcoma, a rare and incurable cancer in his abdomen. He had four tumours removed over Christmas. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2019 Category: Consumer Health News Source Type: news
Adaptimmune gets FDA designation to accelerate development of cancer therapy
The Food and Drug Administration has awarded a key designation to a therapy Adaptimmune is developing for a rare type of cancer.
Adaptimmune's experimental T-cell therapy, called ADP-A2M4, targets synovial sarcoma, a cancer that occurs primarily in the extremities of the arms or legs. About two people out of every one million are diagnosed with the condition annually.
The FDA designated ADP-42M4 as a regenerative medicine advanced therapy. That designation, established as part of the 21st Century… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 3, 2019 Category: Pharmaceuticals Authors: John George Source Type: news
Scientists develop potential new treatment for common soft-tissue childhood cancer
(Trinity College Dublin) CRISPR 'genetic screens' and new approaches to drug design have provided a potential new therapy, which blocks the progression of synovial sarcoma tumors in pre-clinical trials. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 20, 2018 Category: Cancer & Oncology Source Type: news
Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma.
The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma.
“We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer Treatment &am...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
Medical News Today: Synovial sarcoma: Treatment, diagnosis, and research
What is synovial sarcoma, what are the symptoms of synovial sarcoma, and how is it diagnosed? What causes synovial sarcoma and what is the outlook? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 4, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news
Metastatic Synovial Sarcoma of Lung Mimicking PE and DVT Metastatic Synovial Sarcoma of Lung Mimicking PE and DVT
What can we learn from this case of metastatic synovial sarcoma initially misdiagnosed as deep venous thrombosis?Thorax (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
